Format

Send to

Choose Destination
Blood Adv. 2019 Jul 9;3(13):1926-1929. doi: 10.1182/bloodadvances.2018025726.

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Author information

1
Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO.
2
Children's Minnesota, Minneapolis, MN.
3
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
4
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
5
Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA; and.
6
Children's Hospital of Wisconsin, Milwaukee, WI.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center